このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

UPTAKE - バーチャルケア: リモートモニタリングを備えたバーチャル在宅病院で急性期治療入院を削減 (UPTAKE-VC)

2026年11月5日 更新者:University of Calgary

パーソナライズされたリスクとデジタル ツールを使用して、急性腎臓イベント後の移行をガイドする - バーチャル ケア: リモート モニタリングを備えたバーチャル ホーム ホスピタルにより急性期入院を削減

Method: Randomized Controlled Trial Study Duration: 3 Years Study Centre(s) University of Calgary and University of Alberta Objectives: To fill care gaps by implementing strategies to reduce length of hospital stay, readmission rates, and improve long-term outcomes after Acute Kidney Injury (AKI). Number of Participants: Three Hundred and fifty four (n=354) Diagnosis and Main Inclusion Criteria: Hospitalized adults with AKI at high risk of hospital readmission or death

Study Intervention: Multi-component Digital Health Solutions, including:

  1. Computerized Clinical Decision Support (CDS) and
  2. Virtual Care Delivered through Hospital at Home (VC) Duration of administration: Determined by the Patient's clinical team Reference therapy: Usual Care Statistical Analyses: Descriptive Analysis, Regression

調査の概要

状態

募集

介入・治療

詳細な説明

  1. Background and Rationale

    Acute kidney injury (AKI) is a common and serious complication in hospitals. A major care gap for survivors of AKI is the fragmentation of care that exists as they transition from the hospital to their home. This contributes to a high risk of adverse long-term outcomes, including prolonged hospitalization, high rates of readmission, cardiovascular events, infections, progression to chronic kidney disease (CKD), kidney failure requiring dialysis, and death.

    To address this challenge, the investigators are implementing multi-component digital health solutions including Computerized Clinical Decision Support (CDS) and Digital Remote Patient Monitoring (dRPM) through Virtual Care (VC) programs in Alberta to reduce length of hospital stay and readmission rates and improve long-term outcomes after AKI.

    Evidence of the effectiveness of the two digital health solutions is available from Alberta and international clinical trials. Our team previously implemented a computerized CDS intervention for AKI risk assessment and prevention and achieved improved AKI prevention and reduced AKI incidence after cardiac procedures across the province. The investigators will use a similar approach to identify high risk patients with AKI and provide recommendations to improve the quality of their care, which is well suited to the evolving digital health infrastructure in Alberta.

    Providing hospital-level care at home through Virtual Care (VC) teams has been shown to reduce mortality and readmission rates. Alberta's VC program have existed in both Edmonton and Calgary since 2018 and have reported lower readmission rates, Emergency Department (ED) visits and use of Emergency Medical Services than observed with usual care. Patients reported that the program helped them regain their independence and function. Alberta's VC programs have implemented dRPM technology, which has been further associated with fewer days in hospital and emergency department visits. Patients reported better quality of care using this technology. The framework for dRPM and complex care planning is already in place in Alberta's Virtual Care programs. The investigators intend to utilize these programs to improve transitions of care through early facilitated discharge and enhanced follow-up of patients with AKI at high risk of hospital readmission, who require frequent monitoring and more intensive care strategies during this vulnerable period of transition in care.

  2. Research Question and Objectives

    • Implement and evaluate a transition of care intervention for patients with AKI.
    • Integrate digital health solutions that can achieve levels of monitoring and care in a patient's own home that are comparable to acute care, while transitioning care to the community setting.
    • Reduce the length of hospital stay and risk of hospital readmission for people with AKI.
    • Improve the long-term outcomes after hospitalization with AKI.
  3. Methods

The investigators will evaluate implementation initially in a Vanguard phase to establish feasibility and acceptability of the intervention, followed by an evaluation of implementation and effectiveness of the intervention in a larger Multicenter Randomized Controlled Trial (RCT). High risk patients with AKI and a predicted risk of readmission or death ≥20% will be identified using a Best Practice Alert (BPA) in Connect Care and participants will be randomized to care with or without virtual monitoring through the VC programs. All patients will receive the same baseline interventions refined in the Vanguard phase, while the intervention arm will additionally receive VC with dRPM following discharge.

High risk patients in the intervention arm will be navigated through the transition of care pathway by a trained nurse navigator. Patients will receive dRPM kits, and biometric data will be automatically uploaded to the web-based monitoring platform and reviewed by the nurse navigator. Patients will receive regular virtual assessments via telephone or videoconferencing (via the tablet) after in-patient discharge. Blood tests will be drawn at home by community paramedics as deemed necessary by the clinical team to assess kidney function and monitor for complications of AKI. Should concerns be identified that warrant in-person assessment, paramedic care teams will be sent for assessment and/or intervention. Upon completion of the intervention patients will be assessed for readiness to move to the subacute arms of the program and return to their primary care provider. If ongoing nephrologist or other specialist care is required, the nurse navigator will ensure appropriate follow up is arranged.

研究の種類

介入

入学 (推定)

354

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Director
  • 電話番号:+1 (403) 210. 6730
  • メール:cccr@ucalgary.ca

研究場所

    • Alberta
      • Calgary、Alberta、カナダ、T2N 1N4
        • 募集
        • University of Calgary
        • コンタクト:
        • 主任研究者:
          • Matthew T James, MD PhD FRCPC
      • Edmonton、Alberta、カナダ、T6G 2G3
        • 募集
        • University of Alberta
        • コンタクト:
        • 主任研究者:
          • Neesh Pannu, MD SM FRCPC

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age ≥ 18 years old.
  • AKI identified in hospital using Kidney Disease Improving Global Outcomes (KDIGO) criteria17.
  • Hospitalization > 48 hours.
  • LACE (L= Length patient Stay in the hospital, A= Acuity of Admission of patient in the hospital, C= Comorbidity and E= Emergency Visit.) Score 12 or higher.
  • Meets all inclusion criteria of Virtual Home Hospital programs of Calgary and Edmonton zones.

Exclusion Criteria:

  • Non-Alberta residents.
  • Resides outside the catchment areas for the Calgary and Edmonton Virtual Home Hospital programs.
  • C1 or C2 goals of care.
  • Hospitalization > 30 days.
  • Will be discharged to long-term care.
  • Kidney failure receiving dialysis.
  • Already admitted in Virtual Home Hospital Program

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:ヘルスサービス研究
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Virtual Care

Participants will receive virtual care through Virtual Home Hospital programs in Alberta for their hospital to home transition of care.

Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.

介入なし:Usual Care

Participants will be discharged as per usual care practices from hospital to their home.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
the number of days alive out of hospital
時間枠:Up to 45 days from the date of randomization

the number of days alive out of hospital

Up to 45 days from the date of randomization

二次結果の測定

結果測定
メジャーの説明
時間枠
the time as inpatient in hospital
時間枠:Up to 45 days from the date of randomization

the time as inpatient in hospital

Up to 45 days from the date of randomization
death
時間枠:from the date of randomization up to 45 days, or date of death from any cause, whichever came first,

death records from health administrative data.

from the date of randomization up to 45 days, or date of death from any cause, whichever came first,
hospital readmission
時間枠:Up to 45 days from the date of randomization

hospital readmission records from health administrative data.

Up to 45 days from the date of randomization
Emergency Department visits
時間枠:Up to 45 days from the date of randomization

Emergency Department visit records from health administrative data.

Up to 45 days from the date of randomization
Estimated Glomerular Filtration (eGFR)
時間枠:At 90 days after the date of randomization

eGFR

At 90 days after the date of randomization
Urine Albumin Creatinine Ration (ACR)
時間枠:At 90 days after the date of randomization

ACR laboratory test

At 90 days after the date of randomization
total number of physician visits
時間枠:Up to 45 days from the date of randomization

total number of physician visits

Up to 45 days from the date of randomization
number of physician visits by specialty
時間枠:Up to 45 days from the date of randomization

primary care vs. non-primary care

Up to 45 days from the date of randomization
Changes to medication prescription
時間枠:Up to 45 days from the date of randomization

Changes to medication prescription (including starting, stopping, or dose adjustment) of an Angiotensin-Converting Enzyme Inhibitors (ACEI)/Angiotensin receptor blockers (ARB), diuretic, SGLT2 inhibitor, or NSAID or administration of IV fluid

Up to 45 days from the date of randomization
laboratory testing
時間枠:Up to 45 days from the date of randomization

Number of creatinine/eGFR, electrolytes, and urine protein quantification

Up to 45 days from the date of randomization
patient experience care transition measure
時間枠:At 45 days after the date of randomization

Online Survey

At 45 days after the date of randomization
Euro Qol- 5 Dimension (EQ5D)
時間枠:At 45 days after the date of randomization

Online Survey to assess quality of life mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" to "extreme problems

At 45 days after the date of randomization

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Matthew James, MD、University of Calgary

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年8月10日

一次修了 (推定)

2027年6月30日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2024年7月29日

QC基準を満たした最初の提出物

2024年8月2日

最初の投稿 (実際)

2024年8月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する